Drug intelligence / Profile preview

Technegas

Development stage
Approved
Lead developer
Cyclomedica
Modality
Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Inhalation
01

Overview

**Technegas** is a technetium Tc 99m-labeled ultrafine carbon inhalation aerosol used for nuclear-medicine ventilation imaging. It is prepared immediately before use by adding sodium pertechnetate Tc 99m to a single-use graphite crucible and processing it in the Technegas Plus System, producing a gas-like radioactive carbon aerosol for inhalation. Gamma emissions from technetium Tc 99m enable scintigraphic visualization of regional pulmonary ventilation and, when paired with perfusion imaging, evaluation of pulmonary embolism. Technegas was developed by Cyclomedica and Cyclopharm and is FDA approved in the United States for adults and pediatric patients aged 6 years and older. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022335Orig1s000lbl.pdf))

Brand names
Technegas
Other names
Technegas Aerosoltechnetium Tc 99m-labeled carbon inhalation aerosol99mTc-Technegas
02

Targets

NIS (Human sodium iodide symporter)

Beyond the preview

Go deeper on Technegas.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Technegas.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call